May 2021

Miromatrix Medical Closes $27M Series C Preferred Stock Financing Round

United States - Indiana | United States - Minnesota

Miromatrix Medical, a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve Miromatrix Medical, a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives, closed a $27 million series C preferred stock financing round. Faegre Drinker represented Miromatrix Medical in the matter, with corporate professionals from the Minneapolis and Indianapolis offices providing counsel. The shares of series C preferred stock converted into common stock in connection with the company's recent initial public offering (IPO).

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.